A Retrospective Descriptive Study of Remdesivir Treatment in the Home or Outpatient Setting Among Adult Patients Diagnosed with Coronavirus Disease 2019 (COVID-19)
Infusion Journal · 2024
DOI: 10.70776/kqyl4113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infusion Journal, 2024. Verfasst von Julia Nguyen und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
At the onset of the COVID-19 pandemic, early conflicting evidence complicated implementation of therapy. Despite this dilemma, comprehensive outpatient care including integration of remdesivir treatment was scaled up in a multi-center, integrated health care system. This retrospective descriptive report describes program characteristics and learnings from the frontline.
Methods
Treatment guidelines, medical center policies, implementation checklists, and workflow diagrams were evaluated for cohesion. From a pool of eligible patients with COVID-19 enrolled in remote patient monitoring (RPM), a sub-cohort of patients 18-75 years of age who had received remdesivir between December 15, 2020 and August 31, 2022, either in tents/infusion center staffed with nurses proximate to hospitals or via home infusion was identified via prescription dispensing database.
Results
Among 21,766 patients who enrolled in a COVID-19 pandemic RPM, >95% had positive COVID-19 evaluation and 80% entered the program from the emergency room or hospital. A subset of 1,776 patients was treated with remdesivir of which 1,427 (80%) received treatment before the FDA expanded indication. Highest outpatient remdesivir quantity dispensed occurred between July 2022 and December 2022 associated with prevalence of the highly transmissible Omicron and subvariants. Average outpatient remdesivir treatment duration was 2.59 days.
Conclusions
Rapid implementation of comprehensive outpatient care of COVID-19 was facilitated by multiple factors including expeditious adoption of RPM and telehealth to support traditional home health and advanced medical care at home. While patients treated with remdesivir comprised a small percentage of all RPM patients, this critically timed option during recurrent surges helped to relieve strained hospital resources. Keywords: COVID-19, remdesivir, home infusion, outpatient, implementation
Zitieren
APA
Nguyen, J., Hechter, R., Grant, D. L., Shi, J., Portugal, C., & Towner, W. (2024). A Retrospective Descriptive Study of Remdesivir Treatment in the Home or Outpatient Setting Among Adult Patients Diagnosed with Coronavirus Disease 2019 (COVID-19). Infusion Journal. https://doi.org/10.70776/kqyl4113
Vancouver
Nguyen J, Hechter R, Grant DL, Shi J, Portugal C, Towner W. A Retrospective Descriptive Study of Remdesivir Treatment in the Home or Outpatient Setting Among Adult Patients Diagnosed with Coronavirus Disease 2019 (COVID-19). Infusion Journal. 2024. doi:10.70776/kqyl4113
BibTeX
@article{Nguyen2024,
author = {Nguyen, Julia and Hechter, Rulin and Grant, Deborah Ling and Shi, Jiaxiao and Portugal, Cecilia and Towner, William},
title = {A Retrospective Descriptive Study of Remdesivir Treatment in the Home or Outpatient Setting Among Adult Patients Diagnosed with Coronavirus Disease 2019 (COVID-19)},
journal = {Infusion Journal},
year = {2024},
doi = {10.70776/kqyl4113}
}
EUVIMED